Tengonermin
- Generic Name
- Tengonermin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1960461-99-7
- Unique Ingredient Identifier
- 2YQ0811D7K
- Background
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration.
NGR-hTNF specifically targets angiogenic tumor blood vessels using the NGR motif. Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells. A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity.
- Associated Conditions
- -
- Associated Therapies
- -
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 14
- Registration Number
- NCT03804866
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milan, Italy
🇮🇹Ospedale San Raffaele, Milan, Italy
🇮🇹Istituto Nazionale Tumori IRCCS Fondazione "Giovanni Pascale", Naples, Italy
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Andres J. M. Ferreri
- Target Recruit Count
- 28
- Registration Number
- NCT03536039
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
- Conditions
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 137
- Registration Number
- NCT01358084
- Locations
- 🇮🇹
Ospedale Santo Spirito, Casale Monferrato, Alessandria, Italy
🇩🇪Asklepios Fachkliniken München-Gauting, München-Gauting, Germany
🇮🇹Istituto Clinico Humanitas, Rozzano, Milan, Italy
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 119
- Registration Number
- NCT01358071
- Locations
- 🇬🇧
Beatson Oncology Centre, Gartnavel Hospital, Glasgow, Scotland, United Kingdom
🇬🇧Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 121
- Registration Number
- NCT00994097
- Locations
- 🇮🇹
Fondazione San Raffaele del Monte Tabor, Milan, Italy
🇮🇹Istituto Europeo Oncologico, Milan, Italy
🇮🇹Istituto Nazionale per la ricerca sul cancro, Genoa, Italy
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 48
- Registration Number
- NCT00878111
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT00675012
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria San Martino, Genoa, Italy
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 40
- Registration Number
- NCT00484211
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
🇮🇹Fondazione San Raffaele del Monte Tabor, Milan, Italy
🇮🇹Istituto Europeo Oncologico, Milan, Italy
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT00484276
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
🇮🇹Istituto Nazionale dei Tumori, Milan, Italy
🇮🇹Fondazione San Raffaele del Monte Tabor, Milan, Italy
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- AGC Biologics S.p.A.
- Target Recruit Count
- 37
- Registration Number
- NCT00484432
- Locations
- 🇮🇹
Policlinico Universitario A. Gemelli, Rome, Italy
🇮🇹Fondazione San Raffaele del Monte Tabor, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.